These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24888812)

  • 1. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
    Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
    J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
    Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
    Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bicalutamide].
    Taéron C
    Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
    [No Abstract]   [Full Text] [Related]  

  • 4. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
    Lau YK; Chadha MK; Litwin A; Trump DL
    J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial [
    Boers J; Venema CM; de Vries EFJ; Hospers GAP; Boersma HH; Rikhof B; Dorbritz C; Glaudemans AWJM; Schröder CP
    Eur J Cancer; 2021 Feb; 144():151-161. PubMed ID: 33341447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bicalutamide].
    Kotake T
    Nihon Rinsho; 2000 Jul; 58 Suppl():216-22. PubMed ID: 11022717
    [No Abstract]   [Full Text] [Related]  

  • 8. Primary signet-ring cell/histiocytoid carcinoma of the eyelid expressing androgen receptors and treated with bicalutamide.
    Sakamoto K; Ito T; Tanioka F; Fukamizu H; Tokura Y
    J Dermatol; 2017 Sep; 44(9):e230-e231. PubMed ID: 28543368
    [No Abstract]   [Full Text] [Related]  

  • 9. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
    Sheth H; Kumar P; Shreenivas A; Sambath J; Pragya R; Madre C; Athikari N; Khandare H; Peshattiwar V; Datar R; Limaye S
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036229
    [No Abstract]   [Full Text] [Related]  

  • 10. Bicalutamide with radiotherapy for prostate cancer.
    Brower V
    Lancet Oncol; 2017 Mar; 18(3):e141. PubMed ID: 28190764
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
    Yoshida T
    Int J Urol; 2013 Jul; 20(7):714-5. PubMed ID: 23216631
    [No Abstract]   [Full Text] [Related]  

  • 13. [Incorrect about hormone treatment in prostatic cancer].
    Fosså SD; Egey A; Haukaas SA; Angelsen A; Klepp O; Berge V; Axcrona K; Lilleby W
    Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429. PubMed ID: 19247406
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral bicalutamide for female pattern hair loss: A pilot study.
    Fernandez-Nieto D; Saceda-Corralo D; Rodrigues-Barata R; Hermosa-Gelbard A; Moreno-Arrones O; Jimenez-Cauhe J; Ortega-Quijano D; Vano-Galvan S
    Dermatol Ther; 2019 Nov; 32(6):e13096. PubMed ID: 31579984
    [No Abstract]   [Full Text] [Related]  

  • 15. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
    Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Unreliable survival analysis].
    Tretli S; Kvåle R; Hernes E
    Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429-30; author reply 430. PubMed ID: 19247405
    [No Abstract]   [Full Text] [Related]  

  • 17. Photosensitive drug eruption induced by bicalutamide within the UVB action spectrum.
    Sasada K; Sakabe J; Tamura A; Kasuya A; Shimauchi T; Ito T; Hirakawa S; Tokura Y
    Eur J Dermatol; 2012; 22(3):402-3. PubMed ID: 22503957
    [No Abstract]   [Full Text] [Related]  

  • 18. The third analysis of the bicalutamide Early Prostate Cancer programme.
    Iversen P;
    BJU Int; 2006 Mar; 97(3):438-9. PubMed ID: 16469002
    [No Abstract]   [Full Text] [Related]  

  • 19. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
    Jaspers HC; Verbist BM; Schoffelen R; Mattijssen V; Slootweg PJ; van der Graaf WT; van Herpen CM
    J Clin Oncol; 2011 Jun; 29(16):e473-6. PubMed ID: 21422415
    [No Abstract]   [Full Text] [Related]  

  • 20. [The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer].
    Sivko AV; Prokhorov AV
    Urol Nefrol (Mosk); 1997; (3):49-52. PubMed ID: 9245060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.